Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study

被引：38

作者：

Flannery, Kyle ^{[1
]}

Boyd, Marley ^{[2
]}

Black-Shinn, Jenny ^{[2
]}

Robert, Nicholas ^{[2
]}

Kamat, Ashish M. ^{[3
]}

机构：

[1] Merck & Co Inc, Kenilworth, NJ 07033 USA

[2] US Oncol Network McKesson Specialty Hlth, The Woodlands, TX 77380 USA

[3] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Urol, Houston, TX 77030 USA

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 12期

关键词：

bladder cancer; cisplatin eligible; patient outcomes; real-world utilization; treatment patterns; PHASE-II TRIAL; TRANSITIONAL-CELL CARCINOMA; UROTHELIAL CARCINOMA; PACLITAXEL; CISPLATIN; CARBOPLATIN; CHEMOTHERAPY; METHOTREXATE; VINBLASTINE; MULTICENTER;

D O I：

10.2217/fon-2018-0654

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.

引用

页码：1323 / 1334

页数：12

共 25 条

[1]

[Anonymous], CLIN PRACT GUID ONC

[2]

[Anonymous], ASCO M S

[3]

[Anonymous], J CLIN ONCOL S

[4] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[5] Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987 [J].

Bellmunt, Joaquim ;

von der Maase, Hans ;

Mead, Graham M. ;

Skoneczna, Iwona ;

De Santis, Maria ;

Daugaard, Gedske ;

Boehle, Andreas ;

Chevreau, Christine ;

Paz-Ares, Luis ;

Laufman, Leslie R. ;

Winquist, Eric ;

Raghavan, Derek ;

Marreaud, Sandrine ;

Collette, Sandra ;

Sylvester, Richard ;

de Wit, Ronald .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1107-1113

[6] Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium:: Results of a randomized phase 2 trial [J].

Dogliotti, Luigi ;

Carteni, Giacomo ;

Siena, Salvatore ;

Bertetto, Oscar ;

Martoni, Andrea ;

Bono, Aldo ;

Amadori, Dino ;

Onat, Haluk ;

Marini, Luca .

EUROPEAN UROLOGY, 2007, 52 (01) :134-141

[7] Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium - A trial of the eastern cooperative oncology group [J].

Dreicer, R ;

Manola, J ;

Roth, BJ ;

See, WA ;

Kuross, S ;

Edelman, MJ ;

Hudes, GR ;

Wilding, G .

CANCER, 2004, 100 (08) :1639-1645

[8] Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma [J].

Faiena, Izak ;

Cummings, Amy L. ;

Crosetti, Anna M. ;

Pantuck, Allan J. ;

Chamie, Karim ;

Drakaki, Alexandra .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 :209-215

[9] The role of taxanes in the management of bladder cancer [J].

Galsky, MD .

ONCOLOGIST, 2005, 10 (10) :792-798

[10]

Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.21492, 10.3322/caac.20107]

← 1 2 3 →